FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3156571518> ?p ?o ?g. }

• W3156571518 endingPage "1178" @default.
• W3156571518 startingPage "1174" @default.
• W3156571518 abstract "In recent robust randomized control trials (RCTs), sodium-glucose cotransporter 2 (SGLT2) inhibitors (empagliflozin, canagliflozin, dapagliflozin, and ertugliflozin) have been shown to dramatically decrease both kidney and cardiovascular (CV) adverse outcomes in patients with diabetic kidney disease, nondiabetic proteinuric kidney disease, and heart failure with reduced ejection fraction—with and without the presence of diabetes (1–6). For decades, both the nephrologist’s and transplant nephrologist’s arsenal for the management of proteinuric kidney disease has been limited to renin-angiotensin-aldosterone system blockade (7). Although SGLT2 inhibitors have taken the nephrology community by storm, patients with kidney transplants (KTs) have been notably excluded from large RCTs (8–10). Pathophysiologically, it seems likely they would also benefit from these apparent wonder drugs, particularly as many patients with KT have proteinuric kidney disease or heart failure. Similar to patients with native kidney disease, CV mortality is the leading cause of death in the KT population (11). Is it time to allow patients with KT to benefit from proposed SGLT2 inhibitor mechanisms, including tubuloglomerular feedback restoration, decreased inflammation and fibrosis, and alteration in energy metabolism, that all culminate in improved CV and kidney outcomes (12)? Here, we review the available data for SGLT2 inhibitor use in patients with KTs and discuss potential benefits and risk of their use in this population.Since 2015, sequential RCTs have demonstrated efficacy of SGLT2 inhibitors in improving both kidney and CV outcomes. A 2020 meta-analysis included six of these RCTs that studied SGLT2 inhibitor use (empagliflozin, canagliflozin, dapagliflozin, and ertugliflozin) in close to 47,000 patients with diabetes (2). In all of the studies included in the meta-analysis, SGLT2 inhibitor use led to a reduction in heart failure hospitalizations, with empagliflozin being the only drug with significant CV death risk reduction. A reduction in kidney outcomes was seen with all agents …" @default.
• W3156571518 created "2021-04-26" @default.
• W3156571518 creator A5009931977 @default.
• W3156571518 creator A5012486444 @default.
• W3156571518 creator A5035059653 @default.
• W3156571518 date "2021-07-01" @default.
• W3156571518 modified "2023-10-06" @default.
• W3156571518 title "Sodium-Glucose Cotransporter 2 Inhibitors and Kidney Transplantation: What Are We Waiting For?" @default.
• W3156571518 cites W1980586280 @default.
• W3156571518 cites W2142251736 @default.
• W3156571518 cites W2142261360 @default.
• W3156571518 cites W2146264128 @default.
• W3156571518 cites W2338046714 @default.
• W3156571518 cites W2424539745 @default.
• W3156571518 cites W2500767839 @default.
• W3156571518 cites W2606453842 @default.
• W3156571518 cites W2626446274 @default.
• W3156571518 cites W2808915250 @default.
• W3156571518 cites W2900413769 @default.
• W3156571518 cites W2900600261 @default.
• W3156571518 cites W2905936571 @default.
• W3156571518 cites W2916209949 @default.
• W3156571518 cites W2921909972 @default.
• W3156571518 cites W2922383945 @default.
• W3156571518 cites W2939222610 @default.
• W3156571518 cites W2951094244 @default.
• W3156571518 cites W2969999327 @default.
• W3156571518 cites W2983783768 @default.
• W3156571518 cites W2991847658 @default.
• W3156571518 cites W2999533661 @default.
• W3156571518 cites W3006084195 @default.
• W3156571518 cites W3088173406 @default.
• W3156571518 cites W3092379111 @default.
• W3156571518 cites W3127185910 @default.
• W3156571518 doi "https://doi.org/10.34067/kid.0000732021" @default.
• W3156571518 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35368347" @default.
• W3156571518 hasPublicationYear "2021" @default.
• W3156571518 type Work @default.
• W3156571518 sameAs 3156571518 @default.
• W3156571518 citedByCount "13" @default.
• W3156571518 countsByYear W31565715182021 @default.
• W3156571518 countsByYear W31565715182022 @default.
• W3156571518 countsByYear W31565715182023 @default.
• W3156571518 crossrefType "journal-article" @default.
• W3156571518 hasAuthorship W3156571518A5009931977 @default.
• W3156571518 hasAuthorship W3156571518A5012486444 @default.
• W3156571518 hasAuthorship W3156571518A5035059653 @default.
• W3156571518 hasBestOaLocation W31565715181 @default.
• W3156571518 hasConcept C126322002 @default.
• W3156571518 hasConcept C178790620 @default.
• W3156571518 hasConcept C185592680 @default.
• W3156571518 hasConcept C188053792 @default.
• W3156571518 hasConcept C2780091579 @default.
• W3156571518 hasConcept C2780303639 @default.
• W3156571518 hasConcept C2911091166 @default.
• W3156571518 hasConcept C537181965 @default.
• W3156571518 hasConcept C71924100 @default.
• W3156571518 hasConceptScore W3156571518C126322002 @default.
• W3156571518 hasConceptScore W3156571518C178790620 @default.
• W3156571518 hasConceptScore W3156571518C185592680 @default.
• W3156571518 hasConceptScore W3156571518C188053792 @default.
• W3156571518 hasConceptScore W3156571518C2780091579 @default.
• W3156571518 hasConceptScore W3156571518C2780303639 @default.
• W3156571518 hasConceptScore W3156571518C2911091166 @default.
• W3156571518 hasConceptScore W3156571518C537181965 @default.
• W3156571518 hasConceptScore W3156571518C71924100 @default.
• W3156571518 hasIssue "7" @default.
• W3156571518 hasLocation W31565715181 @default.
• W3156571518 hasLocation W31565715182 @default.
• W3156571518 hasLocation W31565715183 @default.
• W3156571518 hasOpenAccess W3156571518 @default.
• W3156571518 hasPrimaryLocation W31565715181 @default.
• W3156571518 hasRelatedWork W1990329229 @default.
• W3156571518 hasRelatedWork W2043010282 @default.
• W3156571518 hasRelatedWork W2044408772 @default.
• W3156571518 hasRelatedWork W2114046963 @default.
• W3156571518 hasRelatedWork W2378019284 @default.
• W3156571518 hasRelatedWork W2381315121 @default.
• W3156571518 hasRelatedWork W2382568077 @default.
• W3156571518 hasRelatedWork W2388986009 @default.
• W3156571518 hasRelatedWork W2407111357 @default.
• W3156571518 hasRelatedWork W3030709858 @default.
• W3156571518 hasVolume "2" @default.
• W3156571518 isParatext "false" @default.
• W3156571518 isRetracted "false" @default.
• W3156571518 magId "3156571518" @default.
• W3156571518 workType "article" @default.